Skip to main content

Table 1 Baseline Participant Characteristics

From: Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study

CharacteristicsPersistent PTH (n = 100)
Age, mean (SD), y35.1 (11.3)
Male/Female, %25/75
Body Mass Index, mean (SD), kg/m225.9 (5.3)
Employment Status
 Full-time employed, %38
 Part-time employed, %39
 Unemployed, %21
 Retired, %2
Education
 Years of education, mean (SD), y14.7 (2.9)
 No education besides completion of secondary school or high school, %14
 Skilled labor, %28
 Bachelor’s degree, %31
 Higher education, %27
Injury Cause
 Fall, %33
 Motor vehicle collision, %25
 Sports-related injury, %18
 Violence/assault, %5
 Other unintentional injury, %19
Disease History
 Time since mild traumatic brain injury, mean (SD), month59 (54)
 Current acute medication use, No.89
 Current preventive medication use, No.43
 History of preventive medication use, No.74
  No drug failures, %14
  Failure of ≥1 drug, %86
  Failure of ≥2 drugs, %57
  Failure of ≥3 drugs, %35
  Failure of ≥4 drugs, %19
Satisfaction with Current Treatment Status, %21
Self-Rated Health
 Excellent, %4
 Great, %13
 Good, %40
 Rather poor, %30
 Poor, %13
Medico-Legal Issues / Litigation
 Ongoing litigation, %39
 Ended litigation, %39
  Improvement in headache following end of litigation, No. (%)2 (5.1)
Headache Phenotypes
 Chronic migraine-like, %53
 Episodic migraine-like, %1
 Episodic migraine-like combined with chronic TTH-like, %27
 Episodic migraine-like combined with frequent TTH-like, %6
 Chronic TTH-like, %13
Aura, %11
Family History of Primary Headache Disorders, %31
\